Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
Developing new neurophysiological assays to bridge gaps in mental health treatment translation, enhancing therapeutic development efficiency and effectiveness.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 21, 2025 (New/Renewal/Resubmission) | June 20, 2025 (New/Renewal/Resubmission)
Funding Amounts: No budget cap; budgets must reflect actual project needs. UG3 phase: 1–3 years; UH3 phase: up to 3 years; total project period not to exceed 5 years.
Summary: Supports development and cross-species evaluation of neurophysiological assays to bridge translational gaps in mental health treatment development.
Key Information: UG3/UH3 phased cooperative agreement; clinical trial optional; milestone-driven; strong data sharing and cross-species rigor required.
Description
This NIH funding opportunity supports the development, optimization, and evaluation of novel neurophysiological assays that can be used as translational tools in the development of treatments for mental disorders. The initiative aims to address the disconnect between preclinical (animal) and clinical (human) measures in the therapeutic development pipeline by supporting proof-of-concept studies that identify and validate in vivo brain assays relevant to mental health. The ultimate goal is to improve the efficiency and predictive value of the therapeutic development process, accelerating the discovery of effective treatments for mental disorders.
Projects must involve both healthy humans and at least one other species relevant to the therapeutic development pipeline, with a focus on measures that are evolutionarily conserved and can be objectively assessed across species. The program uses a two-phase, milestone-driven UG3/UH3 cooperative agreement mechanism, with NIH staff providing substantial involvement and oversight.
